IP Library Granted Patent US 11,033,581
Granted Patent B2
US 11,033,581 · App. 16/849,614 · Granted Jun 15, 2021

Methods and treatment of trauma adverse events with oxygen reduced blood

Inventors: Andrew Dunham (Lexington, MA); Tatsuro Yoshida (Lexington, MA)
Assignee: Hemanext Inc.
A61K35/14A61P7/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,033,581
App. No.
16/849,614
Granted
Jun 15, 2021
Kind
B2
Abstract

Methods for the reversal of hemorrhagic shock or hemorrhagic trauma. Methods for restoring mean arterial pressure to a normal range and reducing trauma adverse risks in a patient through the administration of oxygen reduced blood compositions.

Claims (27)

1. A method for reducing the amount of stored blood needed for transfusion in a hemorrhagic trauma patient in need thereof comprising:

a. obtaining blood having an oxygen saturation of 20% or less;

b. storing said blood under anaerobic conditions to form hypoxically stored blood; and

c. providing said hypoxically stored blood to a trauma patient in need of a blood transfusion;

wherein said hemorrhagic trauma patient in need thereof has elevated blood lactate levels and is in a shock state, and

wherein said elevated blood lactate levels are reduced and said shock state of said hemorrhagic trauma patient is reversed using a reduced amount of hypoxically stored blood compared to conventionally stored blood.

2. The method of claim 1 , wherein the oxygen saturation of said blood is reduced by deoxygenation prior to said storing.

3. The method of claim 1 , wherein said blood is whole blood, leukoreduced RBCs, platelet reduced RBCs, or leukocyte and platelet reduced RBCs.

4. The method of claim 1 , wherein the amount of stored blood needed by said hemorrhagic trauma patient is reduced by at least 10% relative to the amount of conventionally stored blood.

5. The method of claim 1 , wherein the amount of stored blood needed by said hemorrhagic trauma patient is reduced by at least 30% relative to the amount of conventionally stored blood.

6. The method of claim 1 , wherein the amount of stored blood needed by said hemorrhagic trauma patient is reduced by at least 50% relative to the amount of conventionally stored blood.

7. The method of claim 1 , wherein a hemodynamic function of said hemorrhagic trauma patient is stabilized.

8. The method of claim 1 , wherein a hemodynamic function of said hemorrhagic trauma patient is restored.

9. The method of claim 1 , wherein said reduction of said elevated blood lactate levels in said hemorrhagic trauma patient is by between 10 and 90% compared to a blood lactate level in a hemorrhagic trauma patient receiving the same the amount of conventionally stored blood.

10. The method of claim 1 , wherein said reduction of said elevated blood lactate levels in said hemorrhagic trauma patient is reduced to between 0.5 and 2.5 mmol/L post transfusion.

11. The method of claim 1 , further comprising reducing an elevated blood glucose levels of said hemorrhagic trauma patient to between 70 and 120 mg/dL.

12. The method of claim 1 , further comprising preventing increased levels of a liver enzyme that indicates liver damage or injury in said hemorrhagic trauma patient.

13. The method of claim 12 , wherein said liver enzyme is aspartate aminotransferase (AST) level and said AST level is reduced in said hemorrhagic trauma patient by between 1.5 and 10 fold relative to the AST level in a hemorrhagic trauma patient provided with conventionally stored blood.

14. The method of claim 12 , wherein said liver enzyme is alanine aminotransferase (ALT) and said ALT level is reduced in said hemorrhagic trauma patient by between 1.5 and 10 fold relative to the ALT level in a hemorrhagic trauma patient provided with conventionally stored blood.

15. The method of claim 1 , further comprising reducing post transfusion elevated markers of kidney function comprising urine neutrophil gelatinase-associated lipocalin (u-NGAL), serum creatinine, or blood urea nitrogen (BUN) levels in said hemorrhagic trauma patient.

16. The method of claim 1 , further comprising reducing post transfusion CD45+ neutrophil levels in said hemorrhagic trauma patient.

17. The method of claim 1 , further comprising reducing post transfusion blood CXCL1 levels in said hemorrhagic trauma patient.

18. The method of claim 1 , further comprising reducing post transfusion blood IL-6 levels in said hemorrhagic trauma patient.

19. The method of claim 1 , wherein said hemorrhagic trauma patient has a pre-existing or underlying condition selected from the group consisting of diabetes, ischemic heart disease, systemic inflammatory syndrome brought on by trauma or infection, multiple organ failure brought on by trauma or infection, smoke inhalation, chronic pulmonary obstructive disease, a coagulopathy disorder, and an autoimmune disease.

20. The method of claim 1 , wherein said hemorrhagic trauma patient is a blunt force trauma patient.

21. The method of claim 1 , wherein said hemorrhagic trauma patient has a low mean arterial pressure prior to transfusion with said hypoxically stored blood.

22. The method of claim 1 , wherein said storage period is least 3 weeks.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE PROPERTY NUMBER 16/849,615 PREVIOUSLY RECORDED AT REEL: 54790 FRAME: 499. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 6, 2021
From: DUNHAM, ANDREW
To: HEMANEXT INC.
Reel/Frame 055634/0592 →
CONFIRMATORY ASSIGNMENT Recorded Dec 16, 2020
From: DUNHAM, ANDREW
To: HEMANEXT INC.
Reel/Frame 054790/0499 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2020
From: DUNHAM, ANDREW; YOSHIDA, TATSURO
To: HEMANEXT INC.
Reel/Frame 053491/0148 →
Continuity (4)
Continuation 16791697 · Feb 14, 2020
Continuation 16614683
Provisional Application 62508783 · May 19, 2017
Related Publication 20200237818A1 · Jul 30, 2020
Cited By (1)
US 12,582,674